Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 4Small Cell Lung Carcinoma 2Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Oligodendroglioma 1Malignant Solid Tumor 1Glioblastoma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1Advanced Cancer 1

Interventions

Temozolomide 66Radiotherapy 34Carboplatin 22Carmustine 21Bevacizumab 21Irinotecan 18Filgrastim 18Surgical Procedures, Operative 14Vincristine 11Peripheral Blood Stem Cell Transplantation 11Etoposide 11Radiation 10O(6)-benzylguanine 10Magnetic Resonance Spectroscopy 9Lomustine 9Procarbazine 8Erlotinib Hydrochloride 8sargramostim 7IL13-PE38 7Everolimus 7Cyclophosphamide 7Chemotherapy, Adjuvant 7Thiotepa 6Radiotherapy, Intensity-Modulated 6Imatinib Mesylate 6Granulocyte Colony-Stimulating Factor 6Drug Therapy 6Cisplatin 6temsirolimus 5antineoplaston AS 2-1 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Astrocytoma × etirinotecan pegol × Clear all
NCT01663012 2016-02-24

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Stanford University

Phase 2 Completed
20 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡